Fairmount Funds Management LLC - 31 Dec 2025 SCHEDULE 13G/A Report for Inhibikase Therapeutics, Inc. Common Stock, par value $0.001 per share (IKT)

Filing Manager
Fairmount Funds Management LLC
Reporting Manager
Fairmount Funds Management LLC
Security
Inhibikase Therapeutics, Inc. Common Stock, par value $0.001 per share
Symbol
IKT
Shares outstanding
125,869,707 shares
Disclosed Ownership
12,461,101 shares
Ownership
9.9%
Form type
SCHEDULE 13G/A
Filing time
17 Feb 2026, 16:30:15 UTC
Date of event
31 Dec 2025
Previous filing
14 Feb 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Fairmount Funds Management LLC disclosed 9.9% ownership in Inhibikase Therapeutics, Inc. Common Stock, par value $0.001 per share (IKT) on 31 Dec 2025."

Quick Takeaways

  • Fairmount Funds Management LLC filed SCHEDULE 13G/A for Inhibikase Therapeutics, Inc. Common Stock, par value $0.001 per share (IKT).
  • Disclosed ownership: 9.9%.
  • Date of event: 31 Dec 2025.

What Changed

  • Previous schedule filing date: 14 Feb 2025.
  • Current filing was accepted on 17 Feb 2026, 16:30.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (4)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Fairmount Funds Management LLC 9.9% 12,461,101 0 12,461,101 /s/ Peter Harwin Peter Harwin, Managing Member
Fairmount Healthcare Fund II L.P. 9.9% 12,461,101 0 12,461,101 /s/ Peter Harwin Peter Harwin, Member
Peter Harwin 9.9% 12,461,101 0 12,461,101 /s/ Peter Harwin Peter Harwin
Tomas Kiselak 9.9% 12,461,101 0 12,461,101 /s/ Tomas Kiselak Tomas Kiselak

Sponsored